Similar articles

• Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.

  Nesfield SR, Clarke CJ, Hoivik DJ, Miller RT, Allen JS, Selinger K, Santostefano MJ. Nesfield SR, et al. Int J Toxicol. 2005 Sep-Oct;24(5):301-11. doi: 10.1080/10915810500210278. Int J Toxicol. 2005. PMID: 16257850
• Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I.

  Torrey CE, Wall HG, Campbell JA, Kwanyuen P, Hoivik DJ, Miller RT, Allen JS, Jayo MJ, Selinger K, Savina PM, Santostefano MJ. Torrey CE, et al. Int J Toxicol. 2005 Sep-Oct;24(5):313-25. doi: 10.1080/10915810500208264. Int J Toxicol. 2005. PMID: 16257851
• Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse.

  Nesfield SR, Williams TC, Hoivik DJ, Miller RT, Allen JS, Selinger K, Rickert D, Santostefano MJ. Nesfield SR, et al. Int J Toxicol. 2005 Sep-Oct;24(5):341-8. doi: 10.1080/10915810500210401. Int J Toxicol. 2005. PMID: 16257853
• Genetically altered mouse models for identifying carcinogens.

  Tennant RW, Stasiewicz S, Mennear J, French JE, Spalding JW. Tennant RW, et al. IARC Sci Publ. 1999;(146):123-50. IARC Sci Publ. 1999. PMID: 10353386 Review. No abstract available.
• Use of genetically modified mouse models for evaluation of carcinogenic risk: considerations for the laboratory animal scientist.

  Recio L, Everitt J. Recio L, et al. Comp Med. 2001 Oct;51(5):399-405. Comp Med. 2001. PMID: 11924798 Review.